Nitazoxanide
- Generic Name
- Nitazoxanide
- Brand Names
- Alinia, Busulfex
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9N3O5S
- CAS Number
- 55981-09-4
- Unique Ingredient Identifier
- SOA12P041N
- Background
Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
- Indication
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
- Associated Conditions
- Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
- Conditions
- HIV InfectionHepatitis C Infection
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 68
- Registration Number
- NCT00991289
- Locations
- 🇺🇸
Stanford AIDS Clinical Trials Unit CRS, Palo Alto, California, United States
🇺🇸Columbia P&S CRS, New York, New York, United States
🇺🇸Trillium Health ACTG CRS, Rochester, New York, United States
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- Biological: Peginterferon alfa-2a
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2008-10-01
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 40
- Registration Number
- NCT00763568
- Locations
- 🇪🇬
Digestive Disease Center, Tanta, Egypt
Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus
- Conditions
- DiarrheaRotavirus Infection
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2008-05-26
- Lead Sponsor
- Centro Pediatrico Albina de Patino
- Target Recruit Count
- 75
- Registration Number
- NCT00683982
- Locations
- 🇧🇴
Centro Pediatrico Albina Patiño, Cochabamba, Bolivia
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 112
- Registration Number
- NCT00637923
- Locations
- 🇺🇸
Florida Center for Gastroenterology, Largo, Florida, United States
🇺🇸New York Presbyterian-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Palo Alto VA Healthcare System, Palo Alto, California, United States
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 64
- Registration Number
- NCT00495391
- Locations
- 🇺🇸
VA Palo Alto Healthcare System, Palo Alto, California, United States
🇺🇸McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸Nashville Medical Research Institute, Nashville, Tennessee, United States
Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 121
- Registration Number
- NCT00421434
- Locations
- 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
🇪🇬Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
Study of Nitazoxanide in the Treatment of Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2007-01-05
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 50
- Registration Number
- NCT00418639
- Locations
- 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
🇪🇬Cairo Liver & GIT Center, Cairo, Egypt
🇪🇬Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
- Conditions
- Clostridium Difficile
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 114
- Registration Number
- NCT00417872
- Locations
- 🇺🇸
WellStar Infectious Diseases, Marietta, Georgia, United States
🇺🇸The Reading Hospital and Medical Center, West Reading, Pennsylvania, United States
🇺🇸Remington-Davis, Inc., and Riverside Infection Consultants, Inc., Columbus, Ohio, United States
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 40
- Registration Number
- NCT00418054
- Locations
- 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
🇪🇬Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 50
- Registration Number
- NCT00384527
- Locations
- 🇺🇸
Michael E. Debakey VAMC, Houston, Texas, United States
🇺🇸Bay Pines VAMC, Bay Pines, Florida, United States
🇺🇸John D. Dingell VAMC, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.